Maraviroc-containing HIV PrEP regimens safe, well tolerated

August 23, 2017

(HealthDay)—Maraviroc (MVC)-containing HIV pre-exposure prophylaxis (PrEP) regimens are well tolerated for preventing HIV infection in uninfected women, according to a study published online Aug. 22 in the Annals of Internal Medicine.

Roy M. Gulick, M.D., M.P.H., from Weill Cornell Medicine in New York City, and colleagues conducted a phase 2 study of four antiretroviral regimens used as PrEP in 12 clinical research sites among HIV-uninfected women reporting condom-less vaginal or with at least one man with HIV or unknown serostatus. Participants received MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

Eighty-five percent of the 188 participants completed follow-up; 19 percent discontinued their regimen prematurely. The researchers observed no difference among regimens in the number discontinuing and the time to discontinuation. Five MVC, 13 MVC-FTC, nine MVC-TDF, and eight TDF-FTC participants had grade 3 or 4 adverse events; the rates did not differ among regimens. The MVC-TDF group had one death by suicide, which was judged not to be related to study drugs. Sixty percent of the 126 available plasma samples at week 48 showed detectable drug concentrations. There were no new HIV infections.

"Maraviroc-containing PrEP regimens were safe and well tolerated compared with TDF-FTC in U.S. women," the authors write. "Maraviroc-containing PrEP for women may warrant further study."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Maraviroc-containing regimens safe, tolerable when taken for HIV prevention

February 24, 2016
Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk ...

Protection against HSV-2 is added benefit of tenofovir

July 2, 2014
(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the ...

Small changes in eGFR with TDF preexposure prophylaxis

December 23, 2014
(HealthDay)—For HIV-1-uninfected members of serodiscordant couples, tenofovir disoproxil fumarate (TDF) used as preexposure prophylaxis (PrEP) is associated with a small decrease in estimated glomerular filtration rate ...

Patient infected with HIV despite long-term adherence to PrEP

February 2, 2017
(HealthDay)—In a letter to the editor published in the Feb. 2 issue of the New England Journal of Medicine, authors present the case of a Canadian man infected with HIV despite long-term adherence to pre-exposure prophylaxis ...

International study finds high levels of adherence to use of rectal microbicide gel

October 20, 2016
Participants enrolled in a rectal microbicide study were just as likely to follow through using an anti-HIV gel with anal sex as they were to using daily oral pre-exposure prophylaxis (PrEP), according to adherence results ...

Preventive HIV treatment shown effective at health clinics

November 17, 2015
(HealthDay)—Real-world application of pre-exposure prophylaxis (PrEP) medications appears to be effective for the prevention of HIV, but racial discrepancies exist, new research suggests. The studies appear online Nov. ...

Recommended for you

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.